…
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -54.17M | -21.46M | -14.33M | - |
| Minority interest | 0.21M | 0.11M | -0.11M | -0.01M |
| Net income | -52.63M | -21.36M | -14.26M | - |
| Selling general administrative | 24.86M | 17.44M | 11.85M | - |
| Selling and marketing expenses | 8.42M | - | - | - |
| Gross profit | 14.41M | 2.42M | 0.07M | - |
| Reconciled depreciation | 2.63M | 0.77M | 0.11M | - |
| Ebit | 3.29M | -19.72M | -12.34M | -3.38M |
| Ebitda | 5.92M | -18.95M | -12.22M | - |
| Depreciation and amortization | 2.63M | 0.77M | 0.11M | - |
| Operating income | 3.29M | -18.95M | -12.34M | - |
| Other operating expenses | 62.64M | 21.38M | 12.50M | - |
| Interest expense | 0.06M | 0.08M | 0.03M | 0.00M |
| Tax provision | -1.54M | -0.10M | - | - |
| Interest income | 0.06M | - | - | - |
| Net interest income | 0.06M | -0.08M | -0.03M | - |
| Income tax expense | -1.54M | -0.10M | -0.07M | - |
| Total revenue | 37.17M | 8.98M | 0.11M | - |
| Total operating expenses | 39.88M | 21.38M | 12.47M | - |
| Cost of revenue | 22.76M | 6.55M | 0.04M | - |
| Total other income expense net | -57.46M | -2.51M | -2.00M | - |
| Net income from continuing ops | -52.63M | -21.36M | -14.33M | - |
| Net income applicable to common shares | - | -21.25M | -14.17M | -3.39M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 23.63M | 80.99M | 85.48M | 19.45M | 1.17M |
| Intangible assets | 0.95M | 18.10M | 9.74M | 0.66M | 0.57M |
| Other current assets | 1.37M | 0.98M | 0.04M | 0.35M | 0.21M |
| Total liab | 17.22M | 24.57M | 8.54M | 3.20M | 2.48M |
| Total stockholder equity | 6.40M | 56.82M | 77.17M | 16.36M | -1.29M |
| Other current liab | 8.44M | 7.42M | 0.06M | 0.60M | 1.15M |
| Common stock | - | - | 102.43M | 27.25M | 1.40M |
| Capital stock | 0.00M | 0.00M | 102.43M | 27.25M | 1.40M |
| Retained earnings | -142.55M | -90.86M | -38.54M | -17.29M | -2.82M |
| Other liab | - | - | 1.51M | 0.14M | - |
| Good will | 0.00M | 23.37M | 20.05M | 0.43M | - |
| Other assets | - | - | 0.10M | - | - |
| Cash | 4.38M | 9.54M | 37.61M | 15.52M | 0.14M |
| Total current liabilities | 16.28M | 17.45M | 6.12M | 2.74M | 2.23M |
| Net debt | -0.71M | -5.39M | -36.28M | -14.87M | 1.19M |
| Short term debt | 2.73M | 2.27M | 0.43M | 0.33M | 1.08M |
| Short long term debt | 1.93M | 1.09M | 0.02M | 0.25M | 1.03M |
| Short long term debt total | 3.67M | 4.14M | 1.34M | 0.65M | 1.33M |
| Other stockholder equity | 149.09M | 150.42M | 14.38M | 6.36M | 0.11M |
| Property plant equipment | - | - | 4.98M | 0.73M | 0.43M |
| Total current assets | 21.36M | 31.16M | 47.94M | 17.63M | 0.46M |
| Long term investments | 0.00M | 0.73M | 2.67M | - | - |
| Net tangible assets | - | - | 47.38M | 15.27M | -1.57M |
| Short term investments | - | -0.73M | - | - | - |
| Net receivables | 7.10M | 10.55M | 5.60M | 1.22M | 0.11M |
| Long term debt | - | - | - | 0.07M | - |
| Inventory | 8.51M | 10.09M | 3.03M | 0.54M | - |
| Accounts payable | 5.11M | 7.75M | 5.63M | 1.81M | 0.33M |
| Accumulated other comprehensive income | -0.14M | -2.73M | -1.11M | 0.04M | 0.02M |
| Common stock total equity | - | - | - | 27.25M | 1.40M |
| Non currrent assets other | 0.08M | 0.29M | 0.10M | - | 0.28M |
| Non current assets total | 2.26M | 49.83M | 37.54M | 1.82M | 0.71M |
| Capital lease obligations | 1.74M | 3.06M | 1.32M | 0.33M | 0.30M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -15.80M | -2.51M | -2.16M | -2.51M |
| Change to liabilities | - | 3.05M | -0.32M | 1.23M |
| Total cashflows from investing activities | - | -14.55M | -2.16M | -0.52M |
| Net borrowings | - | -0.52M | -1.07M | 1.21M |
| Total cash from financing activities | 4.41M | 58.11M | 25.82M | 1.21M |
| Change to operating activities | - | -1.25M | -0.03M | -0.20M |
| Net income | -52.63M | -21.36M | -14.33M | -3.39M |
| Change in cash | -28.08M | 22.09M | 15.38M | 0.17M |
| Begin period cash flow | 37.62M | 15.52M | 0.14M | - |
| End period cash flow | 9.54M | 37.61M | 15.52M | 0.14M |
| Total cash from operating activities | -15.94M | -20.65M | -8.42M | -0.54M |
| Issuance of capital stock | 4.55M | 42.62M | 30.00M | - |
| Depreciation | 2.63M | 0.77M | 0.11M | 0.03M |
| Dividends paid | - | 2.51M | 0.00M | - |
| Change to inventory | 1.22M | -1.14M | -0.06M | -0.06M |
| Change to account receivables | - | -5.69M | -0.54M | -0.02M |
| Sale purchase of stock | -0.26M | 2.51M | - | - |
| Other cashflows from financing activities | 0.31M | 16.00M | -3.10M | 1.25M |
| Change to netincome | - | 4.87M | 6.58M | 1.81M |
| Capital expenditures | 1.29M | 3.98M | 0.23M | 0.17M |
| Change in working capital | 3.82M | -5.04M | -0.95M | - |
| Stock based compensation | 3.40M | 1.34M | 4.90M | - |
| Other non cash items | 28.38M | 3.74M | 0.03M | - |
| Free cash flow | -17.23M | -24.63M | -8.65M | - |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKKGY Merck KGaA ADR |
-0.22 0.66% |
33.17 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-2.76 1.62% |
167.12 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.17 0.80% |
21.02 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.85 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
3406 SW 26th Terrace, Fort Lauderdale, FL, United States, 33132
954 842 4989
97
| Name | Title | Year Born |
|---|---|---|
| Mr. Luis Merchan | Pres, CEO & Chairman | 1981 |
| Dr. Bernard Raymond Wilson F.C.A., FCA, FCPA, ICD.D, LLD(H) | Advisor | 1943 |
| Mr. Elshad Garayev CPA, CPA | Chief Financial Officer | NA |
| Mr. Matthew S. Cohen | Gen. Counsel | 1966 |
| Ms. Jessie Casner | Chief Marketing Officer | 1988 |
| Mr. James Choe | Chief Strategy Officer | 1979 |
| Mr. Aaron Atin | Corp. Sec. | 1984 |
| Mr. Javier Franco | VP Agriculture | 1968 |
| Ms. Holly Bell | VP of Regulatory Affairs | NA |
| Mr. Clifford A. Starke | CEO & Director | 1985 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.